The Neurogenic Inflammation Mediator Endothelin‐1 Causes Human Skin Barrier Disruption in Atopic Dermatitis via an ETAR / TRPA1 ‐Axis
Authors:
- Rari LeoRLRari Leo
- Anh JochebethAJAnh Jochebeth
- Nabeel AbdulrahmanNANabeel Abdulrahman
- Maha Victor AghaMAMaha Victor Agha
- Febu Elizabeth JoyFJFebu Elizabeth Joy
- Ayda AlHammadiAAAyda AlHammadi
- Shahad M. YounisSYShahad M. Younis
- Sara Al‐HaramiSASara Al‐Harami
- Fareed AhmadFAFareed Ahmad
- Angeliki DatsiADAngeliki Datsi
- Jianghui MengJMJianghui Meng
Abstract
Background: Atopic dermatitis (AD) is a common, relapsing inflammatory skin disease driven by an immune imbalance, microbial dysbiosis, and skin barrier impairment, culminating in (neurogenic) inflammation and itch. We hypothesized that the neuropeptide and pruritogen endothelin‐1 (ET‐1) contributes to AD pathology by impeding skin barrier formation via its cognate receptor ETAR and TRPA1, a cation channel involved in neurogenic inflammation, pain, and itch. Methods: We utilized differentiated human keratinocytes and ex vivo human skin organ cultures in vitro to evaluate the impact of ET‐1 on human skin barrier function. ET‐1 effects were assessed at the RNA level by RT‐qPCR and at the protein level by quantitative immunofluorescence microscopy. Barrier integrity was monitored using real‐time cell analysis and transwell permeability assays. Results: ET‐1 markedly reduced cell resistance in differentiated keratinocytes, an effect abrogated by the ETAR antagonist bosentan. ET‐1 significantly decreased expression of skin differentiation markers filaggrin and loricrin, and tight junction proteins occludin, claudin‐1, and claudin‐4, at mRNA and protein levels. ETAR‐specific siRNA in combination with ET‐1, rescued ET‐1‐mediated downregulation of filaggrin. Furthermore, TRPA1 antagonist HC‐030031 abrogated the impairing effect of ET‐1 on the skin barrier. We observed increased inflammatory responses of ET‐1‐stimulated keratinocytes, suggesting that the ET‐1‐initiated barrier disruption could be mediated by IL‐6 and IL‐1β and induced by TNF‐α. Conclusion: Our findings suggest that a neurogenic inflammation axis ET‐1/ETAR/TRPA1 contributes to skin barrier impairment in AD by repressing differentiation markers and tight junction proteins. Additionally, we demonstrate ETAR‐blockage as a rational therapeutic modality for patients with AD.Keywords
This publication has 56 references indexed in Scilit:
- The renaissance of human skin organ culture: A critical reappraisalDifferentiation, 2018
- Sensory Neurons Co-opt Classical Immune Signaling Pathways to Mediate Chronic ItchCell, 2017
- Enhanced chemosensory sensitivity in patients with idiopathic rhinitis and its reversal by nasal capsaicin treatmentJournal of Allergy and Clinical Immunology, 2017
- Etiology of epithelial barrier dysfunction in patients with type 2 inflammatory diseasesJournal of Allergy and Clinical Immunology, 2017
- Multifactorial skin barrier deficiency and atopic dermatitis: Essential topics to prevent the atopic marchJournal of Allergy and Clinical Immunology, 2016
- Filaggrin loss-of-function mutations are associated with enhanced expression of IL-1 cytokines in the stratum corneum of patients with atopic dermatitis and in a murine model of filaggrin deficiencyJournal of Allergy and Clinical Immunology, 2012
- IL-31 regulates differentiation and filaggrin expression in human organotypic skin modelsJournal of Allergy and Clinical Immunology, 2012
- Cytokine modulation of atopic dermatitis filaggrin skin expressionJournal of Allergy and Clinical Immunology, 2007
- Modern Aspects of Cutaneous Neurogenic InflammationArchives of Dermatology, 2003
- Identification of the ETA Receptor Subtype That Mediates Endothelin-Induced Autocrine Proliferation of Normal Human KeratinocytesBiochemical and Biophysical Research Communications, 1995